Effects of the gout-causing Q141K polymorphism and a CFTR δF508 mimicking mutation on the processing and stability of the ABCG2 protein

Biochemical and Biophysical Research Communications

Volumn 437, Issue 1, 2013, Pages 140-145

  Sarankó, Hajnalka ^a,b   Tordai, Hedvig ^b   Telbisz, Ágnes ^a   Özvegy Laczka, Csilla ^c   Erdos, Gábor ^a,b   Sarkadi, Balázs ^a,b,c   Hegedus, Tamás ^a,b  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c National Blood Center   (Hungary)

Author keywords

ABCG2; Cystic fibrosis; Gout; Polymorphism; Stability; Structure

Indexed keywords

ADENOSINE TRIPHOSPHATASE; BREAST CANCER RESISTANCE PROTEIN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANIMAL CELL; ARTICLE; BINDING SITE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; GENE MUTATION; GENETIC POLYMORPHISM; INSECT CELL; LOW TEMPERATURE; MAMMAL CELL; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN STABILITY; SPECTROSCOPY; WESTERN BLOTTING;

3R; 4-PHENYLBUTYRATE; ABCG2; CFTR; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, ABCC7; G188E, R191Q, AND R193K RESCUE MUTATIONS IN ABCG2-NBD; GOUT; HEK; HUMAN EMBRYONIC KIDNEY 293 CELLS; MALTOSE BINDING PROTEIN; MBP; NBD; NUCLEOTIDE BINDING DOMAIN; PBA; POLYMORPHISM; SF9; SINGLE NUCLEOTIDE POLYMORPHISM; SNP; SPODOPTERA FRUGIPERDA CELLS; STABILITY; STRUCTURE; TMD; TRANSMEMBRANE DOMAIN;

ATP-BINDING CASSETTE TRANSPORTERS; CELL MEMBRANE; CIRCULAR DICHROISM; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FLOW CYTOMETRY; GENETIC PREDISPOSITION TO DISEASE; GOUT; HEK293 CELLS; HUMANS; MUTANT PROTEINS; MUTATION; NEOPLASM PROTEINS; PHENYLBUTYRATES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY; PROTEOLYSIS; TEMPERATURE;

HEXAPODA; MAMMALIA;

EID: 84880506420     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.06.054     Document Type: Article

References (23)

1. Sarkadi B., Homolya L., Szakacs G., Varadi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol. Rev. 2006, 86:1179-1236.
2. Woodward O.M., Kottgen A., Coresh J., Boerwinkle E., Guggino W.B., Kottgen M. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:10338-10342.
3. Kerr I.D., Jones P.M., George A.M. Multidrug efflux pumps: the structures of prokaryotic ATP-binding cassette transporter efflux pumps and implications for our understanding of eukaryotic P-glycoproteins and homologues. FEBS J. 2010, 277:550-563.
4. Ozvegy C., Litman T., Szakacs G., Nagy Z., Bates S., Varadi A., Sarkadi B. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem. Biophys. Res. Commun. 2001, 285:111-117.
5. Imai Y., Nakane M., Kage K., Tsukahara S., Ishikawa E., Tsuruo T., Miki Y., Sugimoto Y. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol. Cancer Ther. 2002, 1:611-616.
6. Kondo C., Suzuki H., Itoda M., Ozawa S., Sawada J., Kobayashi D., Ieiri I., Mine K., Ohtsubo K., Sugiyama Y. Functional analysis of SNPs variants of BCRP/ABCG2. Pharm. Res. 2004, 21:1895-1903.
7. Mizuarai S., Aozasa N., Kotani H. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int. J. Cancer 2004, 109:238-246.
8. Morisaki K., Robey R.W., Ozvegy-Laczka C., Honjo Y., Polgar O., Steadman K., Sarkadi B., Bates S.E. Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother. Pharmacol. 2005, 56:161-172.
9. Basseville A., Tamaki A., Ierano C., Trostel S., Ward Y., Robey R.W., Hegde R.S., Bates S.E. Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter. Cancer Res. 2012, 72:3642-3651.
10. Wakabayashi K., Nakagawa H., Adachi T., Kii I., Kobatake E., Kudo A., Ishikawa T. Identification of cysteine residues critically involved in homodimer formation and protein expression of human ATP-binding cassette transporter ABCG2: a new approach using the flp recombinase system. J. Exp. Ther. Oncol. 2006, 5:205-222.
11. Woodward O.M., Tukaye D.N., Cui J., Greenwell P., Constantoulakis L.M., Parker B.S., Rao A., Kottgen M., Maloney P.C., Guggino W.B. Gout-causing Q141K mutation in ABCG2 leads to instability of the nucleotide-binding domain and can be corrected with small molecules. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:5223-5228.
12. Serohijos A.W., Hegedus T., Aleksandrov A.A., He L., Cui L., Dokholyan N.V., Riordan J.R. Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:3256-3261.
13. Rabeh W.M., Bossard F., Xu H., Okiyoneda T., Bagdany M., Mulvihill C.M., Du K., di Bernardo S., Liu Y., Konermann L., Roldan A., Lukacs G.L. Correction of both NBD1 energetics and domain interface is required to restore DeltaF508 CFTR folding and function. Cell 2012, 148:150-163.
14. Varga K., Goldstein R.F., Jurkuvenaite A., Chen L., Matalon S., Sorscher E.J., Bebok Z., Collawn J.F. Enhanced cell-surface stability of rescued DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) by pharmacological chaperones. Biochem. J. 2008, 410:555-564.
15. Izsvak Z., Ivics Z., Plasterk R.H. Sleeping beauty, a wide host-range transposon vector for genetic transformation in vertebrates. J. Mol. Biol. 2000, 302:93-102.
16. Ozvegy C., Varadi A., Sarkadi B. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation. J. Biol. Chem. 2002, 277:47980-47990.
17. Muller M., Bakos E., Welker E., Varadi A., Germann U.A., Gottesman M.M., Morse B.S., Roninson I.B., Sarkadi B. Altered drug-stimulated ATPase activity in mutants of the human multidrug resistance protein. J. Biol. Chem. 1996, 271:1877-1883.
18. Ozvegy-Laczka C., Laczko R., Hegedus C., Litman T., Varady G., Goda K., Hegedus T., Dokholyan N.V., Sorrentino B.P., Varadi A., Sarkadi B. Interaction with the 5D3 monoclonal antibody is regulated by intramolecular rearrangements but not by covalent dimer formation of the human ABCG2 multidrug transporter. J. Biol. Chem. 2008, 283:26059-26070.
19. Sarkadi B., Price E.M., Boucher R.C., Germann U.A., Scarborough G.A. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J. Biol. Chem. 1992, 267:4854-4858.
20. Lim M., McKenzie K., Floyd A.D., Kwon E., Zeitlin P.L. Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids. Am. J. Respir. Cell Mol. Biol. 2004, 31:351-357.
21. DeCarvalho A.C., Gansheroff L.J., Teem J.L. Mutations in the nucleotide binding domain 1 signature motif region rescue processing and functional defects of cystic fibrosis transmembrane conductance regulator delta f508. J. Biol. Chem. 2002, 277:35896-35905.
22. Zhang F., Kartner N., Lukacs G.L. Limited proteolysis as a probe for arrested conformational maturation of delta F508 CFTR. Nat. Struct. Biol. 1998, 5:180-183.
23. Hegedus T., Aleksandrov A., Cui L., Gentzsch M., Chang X.B., Riordan J.R. F508del CFTR with two altered RXR motifs escapes from ER quality control but its channel activity is thermally sensitive. Biochim. Biophys. Acta 2006, 1758:565-572.